SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 951-953. Prepublished online as a Blood First Edition Paper on October 10, 2006; DOI 10.1182/blood-2006-03-013136. This Article Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2006-03-013136v1 109/3/951    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Weng, W.-K. Articles by Levy, R. Search for Related Content PubMed PubMed Citation Articles by Weng, W.-K. Articles by Levy, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 28, 2006 Accepted August 27, 2006 Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy Wen-Kai Weng*, Debra Czerwinski, and Ronald Levy Dept of Internal Medicine, Stanford University School of Medicine, Stanford, CA * Corresponding author; email: wkweng{at}stanford.edu. We have reported that anti-idiotype antibody response and FcRIIIa 158 Valine/Valine (V/V) genotype both correlate with better outcome in a group of 136 follicular lymphoma patients receiving idiotype vaccination after induction chemotherapy. Here, we examined whether this correlation is related in any way to the chemotherapy response. In CR patients, the 5-year progression free survival (PFS) was 69% for patients with antibody response and/or V/V genotype while only 40% for patients with neither, median time to progression (TTP) 10.47 vs 3.46 years (p=0.012). In PR patients, the 5-year PFS was 57% for patients with antibody response and/or V/V genotype and 17% for patients with neither, median TTP not reached vs 1.31 years (p=0.0001). This study further confirms the strong association of clinical outcome with antibody response and with the functionally more active form of the Fc receptor in patients receiving idiotype vaccination regardless their response to induction chemotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al. Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia J. Immunol., May 1, 2008; 180(9): 6374 - 6384. [Abstract] [Full Text] [PDF] L. Binyamin, R. K. Alpaugh, T. L. Hughes, C. T. Lutz, K. S. Campbell, and L. M. Weiner Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy J. Immunol., May 1, 2008; 180(9): 6392 - 6401. [Abstract] [Full Text] [PDF] E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab Haematologica, August 1, 2007; 92(8): 1127 - 1130. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020